Bayer and Fujifilm scored exits as the cancer treatment developer floated on the Nasdaq Global Select Market at the top of its range.
Century Therapeutics, a US-based cancer immunotherapy developer backed by pharmaceutical and chemical group Bayer and optics and medical engineering group Fujifilm, has gone public in a $211m initial public offering. The company issued 10.6 million shares on the Nasdaq Global Select Market priced at $20 per share, which was the upper end of the offering’s…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.